All trials
NCT07214727PHASE1RECRUITING

A Study to Evaluate ALN-5288 in Patients With Alzheimer's Disease

✨ Plain-English version on the way · ~2 days

We're still translating this one. In a couple of days, you'll see what this trial actually tests — and whether it matters for APOE4 carriers like you. For now, here's the sponsor's own description:

The purpose of this study is to: * Evaluate the safety and tolerability of intrathecal (IT) ALN-5288 in patients with Alzheimer's Disease (AD) * Evaluate the pharmacodynamic (PD) and pharmacokinetic (PK) effects of ALN-5288 after dose administration
Read full record on ClinicalTrials.gov

Eligibility check — Phoenix members

Phoenix members see for THIS trial:

  • APOE genotype match
  • Cognitive status fits inclusion
  • Specific exclusions flagged
  • Distance to nearest site
Check my eligibility — become a member
Sites
11 locations
Start
2025-10-15

Interventions tested

  • DRUGALN-5288
  • DRUGPlacebo
View full record on ClinicalTrials.gov

We use cookies to enhance your experience.